[Skip to Navigation]
Invited Commentary
March 2016

Shaping Patients’ Perspective of Medical Marijuana for Glaucoma Treatment

Author Affiliations
  • 1Scheie Eye Institute, Leonard Davis Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 2Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland
JAMA Ophthalmol. 2016;134(3):265-266. doi:10.1001/jamaophthalmol.2015.5290

In this issue of JAMA Ophthalmology, Belyea and colleagues1 provide insight into the perspectives of patients with glaucoma on the use of marijuana for the potential treatment of their disease. This insight is undoubtedly timely given the recently expanding legalization of medical marijuana throughout the United States. As Belyea et al1 acknowledge, this strong public-driven shift toward legalization of medical marijuana seems to clash with the relatively weak scientific evidence supporting its therapeutic use, particularly for treatment of glaucoma. However, more than 20 states have now legalized medical marijuana, creating a supportive landscape for its use in growing segments of the population.

Add or change institution